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Sergio Giralt12,13Important advances in allogeneic hematopoietic death following allogeneic HSCT, and it remains the
stem cell transplantation (HSCT) over the past 20
years have substantially reduced the risk of treatment-
related morbidity and mortality. However, in that
same time period, the incidence of relapse has not
changed significantly, despite the introduction of
donor lymphocyte infusion (DLI) as a specificmodality
to treat relapse [1,2]. Relapse is the leading cause of1Experimental Transplantation and Immunology Branch,
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6/j.bbmt.2010.02.025primary cause of death among patients surviving
more than 2 year after allogeneicHSCT [1].Moreover,
the risk of relapse and disease progression is signifi-
cantly higher following nonmyeloablative and
reduced-intensity conditioning (RIC) than after
myeloablative allogeneic HSCT for almost all malig-
nant diseases for which these regimens have been
employed [3-5].
Prior to the introduction of DLI, the primary
approaches to the treatment of relapse were withdrawal
of immune suppression, use of conventional chemo-
therapeutic agents, and consideration of a second
allogeneic HSCT [6,7]. Initial reports demonstrated
DLI was dramatically effective for relapsed chronic
phase chronic myelogenous leukemia (CML), and
provided optimism that there was an efficacious
modality that could potentially benefit the majority of
patients who experienced relapse following allogeneic
HSCT. This enthusiasm was quickly dampened by
the subsequent reports that DLI benefited only
a minority of patients with diseases other than CML
[8,9]. The optimal dose, frequency, and cell type for
DLI remains to be determined [9]. Various attempts
have beenmade to augment the potency and specificity
of DLI; however, the utilization and efficacy remains
essentially unchanged [10-12].
The one major advancement that has occurred
over the past 20 years, relative to the problem of re-
lapse after allogeneic HSCT, is our improved under-
standing of the biology that underlies the graft-
versus-leukemia/tumor (GVT) effect [13,14].
Research on the biology of GVT, such as the role of
killer immunoglobulin receptors, could eventually
have significant clinical impact [15]. Other factors, in-
dependent of GVT, also affect relapse. These include
specific disease biology, tumor microenvironment,
sanctuary sites, and chemotherapy and/or563
564 Biol Blood Marrow Transplant 16:563-564, 2010M. R. Bishop et al.radiotherapy resistance. How these factors interrelate
to predict long-term disease control versus disease re-
currence (early versus late) is uncertain and requires
further study. The experience with both syngeneic
and autologous HSCT demonstrated that the condi-
tioning regimen is important for long-term disease
control [16]. However, as more and more patients
are undergoing allografting with reduced-intensity
and nonmyeloablative conditioning regimens, disease
progression and relapse will increasingly be an impor-
tant cause of treatment failure. This has led to the use
of strategies, such as administration of ‘‘targeted
agents’’ and immunomodulatory agents posttransplan-
tation to reduce the risk of relapse associated with
these conditioning regimens.
It was with the recognition that relapse after alloge-
neic HSCT is a significant clinical problem, that there
is growing understanding of the mechanisms underly-
ing the biology of relapse, and the perception that there
was a lack of coordination of efforts in the basic, trans-
lational, and clinical researchon relapse, that the idea of
organizing a workshop on this subject emerged. Ini-
tially starting as an informal query, it rapidly became
apparent there was significant interest in this topic,
and thereweremany individualswhowere highly inter-
ested in participating in such an effort. An initial orga-
nizational meeting hosted by the National Cancer
Institute (NCI) took place in San Francisco during
the 2008 Annual Meeting of the American Society of
Hematology. Subsequent meetings led to the forma-
tion of separate committees addressing the biology, ep-
idemiology, prevention, monitoring, and treatment of
relapse. Committee chairs recruited various members
both within and, importantly, outside the transplant
community with diverse expertise relative to their spe-
cific committee topic. Each committee was given the
charge of reviewing and summarizing the available sci-
entific data on their specific topic, identifying ongoing
research of great interest and potential, as well as where
research was felt to be deficient. The results of these ef-
forts were presented and discussed at a workshop spon-
sored by the NCI occurring November 2-3, 2009, in
Bethesda, MD, and included over 250 international
participants. The goals of this workshopwere to review
the current state of the science, to present respective
committee recommendations, and to have debate and
discussion among all of the workshop participants
with the ultimate goal of promoting a coordinated
research effort to address the problem of relapse.
Over the followingmonths a summary of each commit-
tee’s findings and recommendations will be presented
in the Biology of Blood and Marrow Transplantation.
The purpose of these reports is multifold, including
providing a scientific review on various topics related
to relapse after allogeneic HSCT, but more impor-
tantly to stimulate discussion and identify and priori-
tize research efforts on this important clinical problem.ACKNOWLEDGMENTS
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